The document discusses recommendations for Gedeon Richter, a generics pharmaceutical company, to address challenges from industry trends toward lower-cost generics and biosimilars. It recommends that Gedeon Richter partner with a biotech firm to develop a biosimilars business, outsource generics manufacturing to India to lower costs, and focus resources on the higher-growth biosimilars market to strengthen its position and financial performance.
This is the Strategic Dilemma project my Executive MBA team presented in April 2009. The company we were working with is in the Pharmaceutical Drug Development Industry. There are slides showing the timeline for drug development and how this company could reduce the time to market for drugs.
Proven solution to antibiotic resistance in multiple markets
Strong foothold in feedstock verticals with established long-term partners
Solid growth strategy with proven execution
Recurring revenue from repeat orders shows growth trajectory
Experienced management team with ability to deliver results
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
This is the Strategic Dilemma project my Executive MBA team presented in April 2009. The company we were working with is in the Pharmaceutical Drug Development Industry. There are slides showing the timeline for drug development and how this company could reduce the time to market for drugs.
Proven solution to antibiotic resistance in multiple markets
Strong foothold in feedstock verticals with established long-term partners
Solid growth strategy with proven execution
Recurring revenue from repeat orders shows growth trajectory
Experienced management team with ability to deliver results
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. In / Out Licensing
3. Partnership / Co- development
4. Divestiture/ Mergers / Acquisition
5. IP Licensing and Sale
6. Funding and Investment Advisory
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions
2. Extensive ‘C’ level network nurtured for over 18 years
3. Global Deal making skills, honed for decades
4. Partners having combined experience of 250+ years
5. Supplementing your bandwidth to save time, effort & cost
95+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
APSA 2012 members insight survey - results finalapsa_australia
These are the survey results from the inaugural annual Australian Pharmaceutical Suppliers Association (APSA) member insight survey. A total of 18 people responded out of a population of 163 members.
Presentation by Noel Harvey, VP R&D, and Al Lauritano, Head of Strategic Technology Partnerships, Becton Dickinson, on January 19, 2015 for mHealth Israel meetup.
Characteristics of the liquid crystals market (A Deep Dive into Merck's LC & ...Merck
Characteristics of the liquid crystals market
Walter Galinat (President of Merck Performance Materials)
Additional info: http://www.merckgroup.com/en/investors/information_day_LC_OLED.html
In deze ETION-inspiratienota verkent Rik De Wulf, content leader business ethics, wat sociale ondernemingen kenmerkt, hoe ze werken aan sociale innovatie en wat ertoe kan bijdragen om hun impact duurzaam te maken
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. In / Out Licensing
3. Partnership / Co- development
4. Divestiture/ Mergers / Acquisition
5. IP Licensing and Sale
6. Funding and Investment Advisory
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions
2. Extensive ‘C’ level network nurtured for over 18 years
3. Global Deal making skills, honed for decades
4. Partners having combined experience of 250+ years
5. Supplementing your bandwidth to save time, effort & cost
95+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
APSA 2012 members insight survey - results finalapsa_australia
These are the survey results from the inaugural annual Australian Pharmaceutical Suppliers Association (APSA) member insight survey. A total of 18 people responded out of a population of 163 members.
Presentation by Noel Harvey, VP R&D, and Al Lauritano, Head of Strategic Technology Partnerships, Becton Dickinson, on January 19, 2015 for mHealth Israel meetup.
Characteristics of the liquid crystals market (A Deep Dive into Merck's LC & ...Merck
Characteristics of the liquid crystals market
Walter Galinat (President of Merck Performance Materials)
Additional info: http://www.merckgroup.com/en/investors/information_day_LC_OLED.html
In deze ETION-inspiratienota verkent Rik De Wulf, content leader business ethics, wat sociale ondernemingen kenmerkt, hoe ze werken aan sociale innovatie en wat ertoe kan bijdragen om hun impact duurzaam te maken
Ppt beleidsnota 74 september 2014-de zeven hoofdzonden van overheidsingrijpen...ETION
"Wanneer doet een overheid er goed aan om in te grijpen in het marktproces?", zo vraagt Geert Janssens, hoofdeconoom van de denktank VKW Metena zich af.
Elke vorm van interventionisme moet zorgvuldig worden afgewogen. De vraag is: op basis van welke criteria?
We kunnen 7 vuistregels hanteren, die ons moeten behoeden voor naïef interventionisme:
1.Regels zijn geen normen
2.Vermijd oeverloze regulering
3.Soms is niets doen beter
4.Laat de markt wat ze beter doet
5.Leunen tegen de wind
6.Op de blaren zitten
7.Extern gezichtspunt
Lees de volledige beleidsnota op: http://www.vkw.be/kennisbank/de-zeven-hoofdzonden-van-overheidsingrijpen
All too often writing HTML and CSS is an afterthought. Its the work that happens after design is finalized and the product has been developed. Its a necessary task in the process to building a website. Wrong.
HTML and CSS are the backbone to every website, and are equally as important as any design or development. At the end of the workshop and after spending time writing some of code attendees will be able to better organize their code, develop modular styles, and work with CSS specificity.
This is a presentation I gave at the Kenya ICT Board's Tandaa Symposium on Local Internet and Mobile Digital Content. The presentation looked at the Internet and Mobile growth since 1995 when the Internet first started in Kenya.
Abstract
This paper deals with the RF (Radio Frequency)-MEMS (Micro-Electro-Mechanical-System) switch design using the coventorware software and its superiority over the existing technologies like PIN Diodes and Field-Effect-Transistors regarding size, power, Isolation and Insertion loss, and graphically how Pull-in voltage affects on the deflection of the switch. Also this paper deals with the fabrication process of the cantilever switch.
Keywords: Etching, Sacrificial Layer, Actuation Voltage, Electrostatic Force, RF Switch, PIN Diodes, Stiction, Isolation and Insertion loss.
Measuring the ROI of Informal Learning - Brandon Hall Group & DoceboDoceboElearning
People learn more through informal channels, on-the-job experiences and coaching than they do through more formal modalities. However, most companies still focus their learning efforts on the classroom.
What opportunities are you missing to help employees learn and retain new knowledge?
SQUARE Pharmaceuticals Ltd Wholly owned subsidiary entry mode Africa Country ...Shorab Hossain
SQUARE Pharmaceuticals Ltd. is the largest pharmaceuticals company in Bangladesh. The company was established in 1958 by Samson H. Chowdhury along with his three friends. At the beginning, the company was a private firm. In 1964 the company converted into a Private Limited Company. The company was converted into a public limited company in 1991 and listed with Dhaka Stock Exchange in 1995. It has been continuously in the 1st position among all national and multinational pharmaceuticals companies since 1985. According to their annual report (April 2014 – March 2015), the turnover of SQUARE Pharmaceuticals was BDT. 30.28 billion (US$ 385.22 million) with about 18.64% market share having a growth rate of about 25.36%.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
Granules India is our typical Multibagger stock, but a Stock
which is a Good Investment due to the enormous growth
opportunities due to increasing capacity and It has a
differentiated business model which will deliver superior
returns in the long run.
Core Investment Thesis :
The company is in pharma space which has been growing at a
fast clip due to rising generics in the developed world as
governments globally are trying to cut healthcare cost. The
company has been a strong player in the API segment with
good pricing power in the commoditized market.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Shriji Polymers is an ISO 9001:2008, ISO 15378:2011 & CE marking certified Pharma packaging company. Shriji’s comprehensive portfolio of products includes HDPE bottles, PP closures, dosage dispensers & specialty products for pharmaceutical applications.
Shriji combines its technical expertise with innovation to deliver solutions that meet customer’s satisfaction.
Shriji has a huge infrastructure spreading over various locations. It has three existing manufacturing units one each in Ujjain, Pithampur and Goa.
16. Increasing competition in generic market and downward pricing pressuresThe Company The Industry The Challenges Recommendations Conclusion
17. Rising Health Care Costs The Company The Industry The Challenges Recommendations Conclusion
18. Industry Structure Shift Traditional Pharmaceutical Industry New Pharmaceutical Industry The Company The Industry The Challenges Recommendations Conclusion Licensing deals & alliances
20. Business Concerns Company facing increased pressure from the trend toward biosimilars Customers demanding less expensive generic drugs The Company The Industry The Challenges Recommendations Conclusion
21. Our Recommendations Prepare Gedeon Richter for industry trend toward biosimilars Company facing increased pressure from the trend toward biosimilars Customers demanding less expensive generic drugs The Company The Industry The Challenges Recommendations Conclusion Partner with biotech firm to develop biosimilar business Outsource generics manufacturing to India
22. Why Biosimilars? The Company The Industry The Challenges Recommendations Conclusion
23. What Are Biosimilars? The Company The Industry The Challenges Recommendations Conclusion
24. GR Experience in Biotech Management made a decision in 2006 to start recombinant biotechnological activities Gedeon Richter and Helm AG acquired Strathmann Biotech for R&D laboratory, pilot plant, and manufacturing unit The Company The Industry The Challenges Recommendations Conclusion Constructed a biotechnology plant in Budapest, operational in 2009 Made a greenfield investment in manufacturing plant in Debrecen for mammalian cell development
25. Potential Partners The Company The Industry The Challenges Recommendations Conclusion Yes No
26. Shifting Focus The Company The Industry The Challenges Recommendations Conclusion
27. Outsource Generics to India Why Outsource? Frees current resources to focus on biosimilars Low costs help GR compete in generics market The Company The Industry The Challenges Recommendations Conclusion Maintains current generics business line
28. Outsource Generics to India Why India? Large pool of skilled labor for low cost to reduce production costs by approximately 40% Indian government building facilities that are compliant to Western standards The Company The Industry The Challenges Recommendations Conclusion Produces 30% of world’s generics – high capacity and capability Substantial export potential with well-established connections to other countries
31. Strategy Analysis Potential Risks/Weaknesses How We Address the Concern Potential of relationship with partners failing Perform extensive analysis of potential biotech partners India has strength in generic manufacturing and distribution; perform frequent quality control Compromising quality of generics business Maintain well-diversified portfolio; have higher rate of success by partnering; by entering the biotech market which is outpacing the traditional pharma market Failure to realize return on biosimilar investment The Company The Industry The Challenges Recommendations Conclusion Increase potential of earning more Sharing profits Extensive analysis of countries prior to entering Country risk
42. Biotech partnering with RG Benefits for Biotech Firm Strong trend towards partnerships Decreases risk of unsuccessful discovery process and increases financial support The Company The Industry The Challenges Recommendations Conclusion Knowledge on regulations in the EU Increases international reach and marketing skills